Denosumab, a human monoclonal antibody to RANKL (receptor activator of nuclear factor 1 kappa B ligand), has been approved for use in patients with recurrent/unresectable/metastatic GCT or for patients in whom surgery would be morbid [46–48]. This evidence concerns the gene TNFSF11 and granular cell tumor.